Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

Hair loss research is important and contributes to overall scientific advancement, benefiting emotional well-being and potentially aiding other medical fields. Treatments mentioned include PP405 and SCUBE3.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

Astaxanthin may cause increased hair shedding, affecting even transplanted hair and eyebrows. The user has tried various treatments for androgenic alopecia, including minoxidil, finasteride, and RU58841.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

Minoxidil with alcohol and propylene glycol was more effective than non-alcohol versions, and RU58841 worked best in a non-water-based solution. Oral finasteride showed better results than topical, despite side effects; microneedling and tretinoin worsened hair loss, and PRP was only helpful when younger.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

Female (37) experiencing hair loss for 5 years, tried max dose of spiro and oral + topical minox without success. Discovered low cortisol and low DHEA levels, seeking functional medicine practitioner for help.

The conversation discusses using NAC and quercetin as supplements for hair loss, with some users also mentioning finasteride. NAC is highlighted for its potential benefits, but concerns about its safety and absorption are also raised.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

Vitamins and minerals like vitamin E, zinc, and iron may aid hair growth, especially in cases of deficiency. Pumpkin seed oil, saw palmetto, horsetail, and AminoMar show some promise for improving hair health and count.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Combining pyrilutamide and alfatradiol might be as effective as finasteride for hair maintenance. The user plans to try this combination alongside minoxidil and keto shampoo, hoping for improved hair thickness.

A user experiencing diffuse thinning since age 18 describes their hair as unhealthy, dry, thin, and hard, with texture changes cycling between good and bad every few weeks. They are not on any medication, only taking vitamins and supplements.

A user shared a DIY recipe for a NutraKos-style amino acid mix as a cost-effective alternative to the expensive product, suggesting it as a complementary supplement for hair loss. Another user argued that proven treatments like finasteride and minoxidil are more reliable, questioning the efficacy of the amino acid mix.

Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.

A combination of pyrilutamide, minoxidil, and alfatradiol is proposed as an effective alternative to finasteride for treating mild to moderate hair loss, claiming to stabilize hair loss and improve thickness without finasteride's side effects. Some users are skeptical about the effectiveness and approval of these treatments, while others are interested in trying them due to finasteride's side effects.

Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

User experienced hair loss since 16, used Fin, Minox, and Nizoral with success but stopped due to side effects. Now using Pur D'or shampoo, Rogaine foam, scalp massages, volumizing spray, and dermarolling for hair maintenance.

OP experienced significant hair regrowth after recovering from iron deficiency anemia and starting minoxidil. They suspect anemia contributed more to their hair loss than androgenetic alopecia (AGA).

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.